In brief
- The United Nations has issued an alert regarding a family of synthetic opioids known as “orphines,” which are not detected by current fentanyl or nitazene test strips.
- The February UNODC advisory describes detections in fourteen countries, but its figure and text disagree on the analogue count. It is not presented as a current inventory and no single total is forced.
- The European Drug Report 2026 confirms a similar trend across the continent, with eighteen deaths linked to orphines between June 2024 and January 2026.
The February 25, 2026 UNODC advisory describes limitations of evaluated nitazene and fentanyl strips against orphines. A negative result cannot guarantee absence; performance depends on compound, concentration and product, without every available brand having been tested here.
A market evolving faster than monitoring tools
Nitazenes have complicated substance analysis for years. Since the first analogue, isotonitazene, was reported to the UNODC early warning system in 2019, thirty-four variants have been registered across at least thirty-seven countries. The problem is that immunoassay strips were designed to recognize a limited group of these compounds, typically isotonitazene and protonitazene. Consequently, a negative result does not guarantee that a sample is free of nitazenes; so-called “desnitazenes,” such as etodesnitazene, often go unnoticed. Furthermore, some commercial strips exhibit cross-reactivity with caffeine at high concentrations—a common heroin adulterant—potentially producing false positives depending on brand and concentration, without estimating frequency here.
Orphines: A step further
On this already complex landscape, a group structurally distinct from both fentanyl and nitazenes has emerged. The first orphine, brorphine, was reported in 2019 and placed under international control in 2022. The February 2026 advisory describes analogues in fourteen countries; its text counts eleven and its figure ten, an unresolved discrepancy here. UNODC incorporated a new structural group into its database. In North America, there has been a notable increase in detections of cychlorphine, both in seizures and fatal overdoses. The European Drug Report 2026, published in June by the European Union Drugs Agency (EUDA), describes the same phenomenon on the continent: since 2024, nine new orphines have been identified, two of which—cychlorphine and spirochlorphine—are under EU investigation, with five non-fatal intoxications and eighteen deaths with confirmed exposure between June 2024 and January 2026. The European agency suggests that the generic controls on nitazenes introduced by China in July 2025 may be pushing the illicit market toward these alternatives.
What this means
Neither the UNODC nor the EUDA presents this as a cause for widespread panic or as a reproach to people who use drugs; they present it as technical data that is essential for substance analysis to remain useful. The UNODC itself emphasizes that test strips are a valuable tool for fostering conversation and connection, but urges users to calibrate their expectations based on the local market and to clearly communicate their limitations, rather than presenting a negative result as a guarantee. For those who choose to use opioids, the practical takeaway is clear: where harm reduction services offer appropriate analytical methods, they may seek specific compounds within their scope and detection limits; laboratory analysis does not guarantee identification of every substance present. Additionally, access to naloxone is important alongside treatment and other support, without establishing a comparative effectiveness ranking here. The freedom to decide what one consumes includes the right to the best information available, and today that information confirms that no single test strip covers the entire spectrum of synthetic opioids currently in circulation.
Source
- UNODC Early Warning Advisory. Increasing nitazene and orphine analogues (synthetic opioids) and the implications for the use of test strips. United Nations Office on Drugs and Crime, February 25, 2026.
- EUDA. New psychoactive substances — the current situation in Europe (European Drug Report 2026). European Union Drugs Agency, June 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
